Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Profit After Tax: 2009-2024

Historic Profit After Tax for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $163.9 million.

  • Catalyst Pharmaceuticals' Profit After Tax rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 52.36%. This contributed to the annual value of $163.9 million for FY2024, which is 129.50% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Profit After Tax stood at $163.9 million for FY2024, which was up 129.50% from $71.4 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Profit After Tax ranged from a high of $163.9 million in FY2024 and a low of $39.5 million during FY2021.
  • In the last 3 years, Catalyst Pharmaceuticals' Profit After Tax had a median value of $83.1 million in 2022 and averaged $106.1 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Profit After Tax soared by 135.24% in 2020, and later slumped by 47.35% in 2021.
  • Catalyst Pharmaceuticals' Profit After Tax (Yearly) stood at $75.0 million in 2020, then slumped by 47.35% to $39.5 million in 2021, then skyrocketed by 110.42% to $83.1 million in 2022, then dropped by 14.05% to $71.4 million in 2023, then skyrocketed by 129.50% to $163.9 million in 2024.